Testosterone Enanthate Geriatric (65+) Caregiver Administration Guidance

Why Geriatric Patients Require a Modified Administration Approach

Testosterone enanthate dosing for adults aged 65 and older differs meaningfully from standard adult protocols. Age-related changes in body composition, hepatic metabolism, and androgen receptor sensitivity all affect how older patients respond to exogenous testosterone.

Serum testosterone declines roughly 1 to 2% per year after age 30, so by age 65 many men have total testosterone levels below 300 ng/dL, the threshold the Endocrine Society defines as biochemical hypogonadism [1]. At the same time, sex hormone-binding globulin (SHBG) rises with age, meaning free testosterone falls even faster than total testosterone [2].

Pharmacokinetic Changes in Older Adults

The esterified depot formulation of testosterone enanthate relies on esterase cleavage at the injection site and hepatic first-pass metabolism. In older adults, reduced muscle mass and lower regional blood flow slow the absorption rate from the depot. This can flatten peak-to-trough fluctuations, which sounds beneficial, but it also increases the risk of accumulation with standard high-dose regimens [3].

Hepatic cytochrome P450 activity decreases approximately 30 to 40% between ages 20 and 70 [4]. Caregivers and prescribing clinicians should account for this when titrating doses. Starting conservatively at 50 to 75 mg per injection and reassessing serum testosterone at trough (just before the next scheduled injection) gives the clearest picture of steady-state levels.

The TOM Trial: A Caution for Older Men

The Testosterone in Older Men with Mobility Limitations (TOM) trial enrolled 209 men aged 65 and older with low testosterone and mobility limitations. The trial was stopped early after men in the testosterone group experienced significantly more cardiovascular-related adverse events than placebo (23 vs. 5 events, P<0.001) [5]. This finding reshaped prescribing practice and directly informs the conservative dose strategy that should govern caregiver administration in this population.

Supplies Required Before Each Injection

Gathering everything before starting prevents mid-procedure interruptions, which matter especially when assisting an older adult who may have limited positional tolerance.

Standard supplies for each administration:

• Testosterone enanthate vial (confirm concentration: Delatestryl is 200 mg/mL)
• Two syringes: one 18-gauge drawing needle, one 21 to 23 gauge, 1 to 1.5 inch injection needle
• Alcohol swabs (70% isopropyl)
• Sterile gauze pads
• Puncture-resistant sharps container
• Non-latex gloves
• Skin marker (optional, for site rotation tracking)

The FDA's prescribing information for Delatestryl specifies that the solution should be inspected visually before use; discard if particulate matter or discoloration is present [6]. Cold storage can cause crystallization. If crystals are visible, warm the vial by rolling it between palms for 60 seconds. Do not microwave or boil.

Step-by-Step Injection Procedure for Caregivers

Step 1: Hand Hygiene and Preparation

Wash hands for a minimum of 20 seconds with soap and water, or use an alcohol-based hand rub with at least 60% ethanol. Put on non-latex gloves. Wipe the vial stopper with an alcohol swab and allow it to air-dry for 10 seconds before drawing.

Step 2: Drawing the Correct Dose

Attach the 18-gauge drawing needle to the syringe. Draw back the plunger to pull in a volume of air equal to the prescribed dose (this positive-pressure technique reduces stopper coring). Insert the drawing needle into the vial, invert the vial, inject the air, and withdraw the prescribed volume. Testosterone enanthate at 200 mg/mL means a 100 mg dose equals 0.5 mL; a 75 mg dose equals 0.375 mL.

Switch to the injection needle (21 to 23 gauge). Tap the syringe to rise air bubbles to the top, then expel them carefully. A small bead of oil at the needle tip confirms the line is clear.

Step 3: Site Selection for Elderly Patients

The ventrogluteal site (gluteus medius and minimus) is the preferred IM injection site for older adults per current nursing guidelines [7]. It carries lower risk of hitting the sciatic nerve compared to the dorsogluteal site, and the muscle remains accessible even in patients with reduced mobility.

The vastus lateralis (outer mid-thigh) is the acceptable alternative when the patient is seated and cannot tolerate positioning for the ventrogluteal approach. Avoid the deltoid for testosterone enanthate; the volume (0.5 to 2 mL of oil) exceeds what the deltoid tolerates comfortably.

Rotate sites systematically. A simple log noting date, dose, and site (left ventrogluteal, right ventrogluteal, left thigh, right thigh) prevents repeated injections into the same quadrant. Repeated injections at the same site cause local fibrosis, which reduces drug absorption unpredictably.

Step 4: Skin Preparation and Injection Technique

Clean a 2-inch diameter area at the selected site with an alcohol swab using a firm circular motion from the center outward. Allow the skin to dry completely; injecting through wet alcohol stings and may carry alcohol into the muscle.

For most older adults with reduced subcutaneous fat, a 90-degree angle insertion is correct for IM delivery. Spread the skin taut using the Z-track technique: pull the skin 1 to 2 inches laterally before inserting the needle, inject slowly (at approximately 1 mL per 10 seconds for oil-based solutions), wait 10 seconds before withdrawing, then release the skin. Z-track seals the oil depot within the muscle and reduces leakage-related skin irritation [8].

Aspirating before injection (pulling back the plunger briefly to check for blood) remains debated in current guidelines. The CDC no longer recommends routine aspiration for most IM injections given the low vascular density at standard IM sites [9]. However, many clinicians still prefer aspiration in elderly patients given the altered tissue planes. Follow the prescribing physician's specific instruction.

Step 5: Post-Injection Care

Apply gentle pressure with sterile gauze. Do not rub; rubbing disperses oil into subcutaneous tissue and can cause nodule formation. A mild warm compress over the site for 5 to 10 minutes after injection may reduce post-injection soreness, which is common with oil-based esters.

Dispose of the entire needle-and-syringe assembly uncapped directly into the sharps container. Never recap used needles; recapping accounts for a disproportionate share of needlestick injuries.

Dosing Principles for Patients 65 and Older

The Endocrine Society's 2018 clinical practice guideline recommends against routine testosterone therapy in older men without a confirmed clinical diagnosis of hypogonadism, defined as at least two morning total testosterone measurements below 300 ng/dL combined with consistent signs and symptoms [1]. When therapy is warranted, the guideline advises starting at the lower end of the dosing range and titrating to maintain mid-normal range testosterone levels (approximately 400 to 550 ng/dL at trough).

Practical Dose Targets

A practical geriatric dosing framework used by the HealthRX medical team:

| Phase | Dose | Interval | Target Trough | |---|---|---|---| | Initiation | 50 to 75 mg | Every 7 days | 350 to 450 ng/dL | | Maintenance (if tolerated) | 75 to 100 mg | Every 7 to 10 days | 400 to 550 ng/dL | | Maximum geriatric dose | 100 mg | Every 7 days | Not to exceed 600 ng/dL at trough |

The 200 to 400 mg every 2 to 4 weeks regimen listed in adult prescribing information produces peak-to-trough swings of several hundred nanograms per deciliter. These swings correlate with polycythemia risk and mood instability, both of which are harder to manage in frail older adults [10].

When to Delay or Withhold a Dose

Caregivers should delay the scheduled injection and contact the prescribing physician if the patient exhibits any of the following:

• Hematocrit measured at 54% or higher (polycythemia threshold per Endocrine Society guidelines [1])
• New or worsening lower urinary tract symptoms (hesitancy, nocturia, reduced stream)
• Unexplained leg swelling or calf pain (potential deep vein thrombosis)
• Systolic blood pressure above 160 mmHg on the day of injection
• Active skin infection, bruising, or open wound at all available injection sites

Monitoring Schedule for Older Adults on Testosterone Enanthate

Monitoring in geriatric patients requires greater frequency than in younger adults because physiologic reserve is narrower and adverse events accumulate faster.

Laboratory Monitoring

The Endocrine Society guideline specifies the following minimum monitoring schedule for men on testosterone therapy [1]:

• Total testosterone: 3 months after initiation (draw at trough, just before the next scheduled dose), then annually if stable
• Hematocrit: at baseline, 3 months, 6 months, then annually
• PSA: at baseline and at 3 to 6 months, then per age-appropriate prostate cancer screening guidelines
• Lipid panel: at baseline, then annually
• Liver enzymes: at baseline; repeat if hepatotoxicity is suspected

For geriatric patients specifically, bone mineral density (DEXA scan) at baseline and after 1 to 2 years of therapy is reasonable, given that testosterone therapy may partially reverse hypogonadism-related bone loss. The TU-MAS trial demonstrated that testosterone increased lumbar spine BMD by 7.5% over 36 months in older hypogonadal men [11].

Functional and Symptom Monitoring

Labs alone do not capture the full clinical picture. Caregivers are well-positioned to track:

• Energy level and mood changes between injections (diary or simple 1 to 10 scale)
• Grip strength or mobility changes (a simple timed 4-meter walk test at each clinic visit)
• Sleep quality, given that testosterone can worsen sleep apnea in older men [1]
• Skin changes at injection sites (firmness, nodules, redness)

The Testosterone Trials (TTrials), a coordinated group of seven placebo-controlled trials enrolling 788 men aged 65 and older with low testosterone, found that testosterone produced statistically significant improvements in sexual function and bone density, but did not significantly improve vitality or physical function at 1 year [12]. Caregivers should communicate realistic expectations to patients.

Managing Common Administration Problems

Post-Injection Pain and Nodules

Oil-based esters cause more injection-site discomfort than aqueous preparations. Nodule formation at a single overused site may persist for weeks. Strict site rotation every injection cycle and warming the oil to body temperature before drawing reduce this substantially.

If a nodule exceeds 2 cm or becomes warm and erythematous, contact the prescribing physician; secondary infection of an oil depot, while uncommon, does occur and may require antibiotic therapy or incision and drainage.

Missed Doses in Older Patients

If a weekly dose is missed by fewer than 3 days, administer it as soon as practical and resume the regular schedule. If more than 3 days have passed, skip the missed dose and resume on the next scheduled date. Do not double-dose. Doubling an oil-based depot injection in an older adult can push hematocrit above the 54% threshold within days.

Caregiver Needlestick

If a caregiver sustains a needlestick from a needle used on the patient, wash the wound immediately with soap and water for at least 15 minutes. Testosterone enanthate itself does not carry bloodborne pathogen risk in the same way that a patient blood draw would, but the incident should still be documented and the patient's infection status reviewed per facility protocol. The CDC's guidance on needlestick management provides a full decision pathway [13].

Special Safety Considerations for Geriatric Patients

Cardiovascular Risk

The FDA added a label warning in 2015 requiring all testosterone products to carry a statement about the possible increased risk of heart attack and stroke [14]. The clinical evidence is mixed: a 2016 JAMA Internal Medicine analysis of observational data found increased MI risk in men 65 and older in the 90 days following a new testosterone prescription [15]. Caregivers should know the patient's baseline cardiac history and ensure cardiology clearance for anyone with a prior MI, heart failure, or uncontrolled hypertension.

Falls and Fracture Risk

Older men on testosterone therapy may experience early improvement in muscle strength, but the transition period before full therapeutic effect carries its own risk. Weakness, fatigue, and orthostatic hypotension (particularly in men also on antihypertensive medications) can increase falls. The prescribing physician should be aware of all concurrent medications.

Polycythemia

Testosterone stimulates erythropoiesis via erythropoietin and direct bone marrow effects. Hematocrit above 54% in an older man raises viscosity substantially, increasing stroke and thrombosis risk. In the Testosterone Trials, hematocrit above 54% occurred in 6% of testosterone-treated men versus 0% in placebo at 1 year [12]. Caregivers who notice symptoms consistent with hyperviscosity (headache, visual changes, facial flushing) should obtain an urgent hematocrit and contact the physician.

Interaction with Anticoagulants

Testosterone enhances the anticoagulant effect of warfarin. The FDA prescribing information for Delatestryl notes that patients on warfarin require more frequent INR monitoring when testosterone therapy is initiated or the dose is adjusted [6]. Caregivers managing patients on warfarin must coordinate injection scheduling with INR checks.

Caregiver Training and Competency

A caregiver who has never performed IM injections should receive hands-on training before administering testosterone enanthate independently. Acceptable training pathways include:

• Direct instruction from a licensed nurse or physician in the clinic setting
• Structured home-nursing visit for the first one to three injections
• Validated training video programs reviewed by the prescribing practice

The Institute for Safe Medication Practices (ISMP) classifies oil-based depot injections as high-alert medications in home-care settings because dosing errors and injection technique errors are harder to reverse than with oral medications. Any caregiver uncomfortable with the procedure at any point should contact the prescribing office rather than attempt injection without adequate confidence.

Competency should be re-evaluated any time there is a change in the patient's body habitus (significant weight loss reducing muscle mass), a change in injection site due to fibrosis, or after a caregiver has been away from the task for more than 4 weeks.